SCHEMBL2589910

SCHEMBL2589910

Fc1ccc(Cn2cc(P(=S)(c3ccccc3)c3ccccc3)c3ccccc32)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 5/20 0.59
ALDH1A1 P00352 4/20 0.54
HTT P42858 3/20 0.54
SMN1; SMN2 Q16637 2/20 0.54
TP53 P04637 1/20 0.54
POLB P06746 2/20 0.52
MAPT P10636 4/20 0.50
CYP19A1 P11511 2/20 0.50
MAPK1 P28482 1/20 0.50
MEN1 O00255 2/20 0.49
KMT2A Q03164 2/20 0.49
LMNA P02545 1/20 0.49
HSP90AA1 P07900 1/20 0.49
PTGS2 P35354 1/20 0.49
KDM4E B2RXH2 1/20 0.48
NPC1 O15118 1/20 0.48
GAA P10253 1/20 0.48
CASP3 P42574 1/20 0.48
RAB9A P51151 1/20 0.48
SENP8 Q96LD8 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2590676 0.74 NPSR1 (1.00) NPSR1ALDH1A1SMN1; SMN2TP53POLB
SCHEMBL12225809 0.74 POLB (0.63) NPSR1ALDH1A1HTTSMN1; SMN2TP53
SCHEMBL30497877 0.72 POLB (0.78) NPSR1ALDH1A1HTTSMN1; SMN2TP53
SCHEMBL16977268 0.71 CYP19A1 (0.61) NPSR1ALDH1A1HTTSMN1; SMN2TP53
SCHEMBL8690446 0.70 ALDH1A1 (1.00) NPSR1ALDH1A1HTTSMN1; SMN2POLB
SCHEMBL1233547 0.70 ALDH1A1 (0.67) ALDH1A1HTTSMN1; SMN2TP53POLB
SCHEMBL6086686 0.70 POLB (0.74) NPSR1ALDH1A1HTTSMN1; SMN2TP53
SCHEMBL3230384 0.69 TP53 (0.80) ALDH1A1HTTSMN1; SMN2TP53POLB
SCHEMBL27933692 0.69 POLB (1.00) NPSR1ALDH1A1HTTSMN1; SMN2TP53
SCHEMBL2932309 0.68 POLB (0.83) ALDH1A1HTTSMN1; SMN2TP53POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2011137220-A1 SMALL MOLECULE NEUROPEPTIDE S ANTAGONISTS FOR THE TREATMENT OF ADDICTIVE DISORDERS, MOOD, ANXIETY AND SLEEP DISORDERS THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2011-11-03 WO disclosed